Jennifer Holter Chakrabarty
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 67 | 0.600 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2014 | 3 | 0.480 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2014 | 7 | 0.480 |
Why?
|
| Polyethylene | 1 | 2014 | 12 | 0.480 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2014 | 4 | 0.470 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 93 | 0.450 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 112 | 0.430 |
Why?
|
| Dideoxynucleosides | 1 | 2011 | 12 | 0.390 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2011 | 26 | 0.380 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 68 | 0.370 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 98 | 0.360 |
Why?
|
| Meningeal Neoplasms | 1 | 2011 | 73 | 0.360 |
Why?
|
| Leukemia | 2 | 2016 | 22 | 0.270 |
Why?
|
| Bone Marrow | 2 | 2016 | 76 | 0.260 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2020 | 16 | 0.170 |
Why?
|
| Transplantation, Homologous | 2 | 2015 | 41 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 36 | 0.150 |
Why?
|
| Humans | 10 | 2022 | 26777 | 0.140 |
Why?
|
| Whole Body Imaging | 1 | 2016 | 5 | 0.140 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2016 | 4 | 0.140 |
Why?
|
| Adult | 4 | 2018 | 7359 | 0.130 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 12 | 0.130 |
Why?
|
| Leukocyte Transfusion | 1 | 2015 | 1 | 0.130 |
Why?
|
| Granulocytes | 1 | 2015 | 6 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 1 | 2015 | 41 | 0.130 |
Why?
|
| Radiation Dosage | 1 | 2015 | 53 | 0.130 |
Why?
|
| Neutropenia | 1 | 2015 | 34 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2015 | 58 | 0.130 |
Why?
|
| Middle Aged | 4 | 2016 | 6796 | 0.130 |
Why?
|
| Female | 5 | 2016 | 14421 | 0.130 |
Why?
|
| Agglutination Tests | 1 | 2014 | 8 | 0.120 |
Why?
|
| Alemtuzumab | 1 | 2014 | 4 | 0.120 |
Why?
|
| Levonorgestrel | 1 | 2014 | 5 | 0.120 |
Why?
|
| Mice, SCID | 1 | 2014 | 59 | 0.120 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 49 | 0.120 |
Why?
|
| Device Removal | 1 | 2014 | 30 | 0.120 |
Why?
|
| Splenectomy | 1 | 2014 | 43 | 0.120 |
Why?
|
| Drug Resistance | 1 | 2014 | 42 | 0.120 |
Why?
|
| Remission Induction | 1 | 2014 | 50 | 0.120 |
Why?
|
| Transplantation, Autologous | 1 | 2014 | 31 | 0.120 |
Why?
|
| Blood Transfusion | 1 | 2014 | 73 | 0.110 |
Why?
|
| Plasma Exchange | 1 | 2014 | 103 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 290 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 225 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 130 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 464 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 140 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2020 | 2426 | 0.100 |
Why?
|
| Neoplasms | 1 | 2018 | 748 | 0.080 |
Why?
|
| Young Adult | 1 | 2014 | 2576 | 0.070 |
Why?
|
| Whole-Body Irradiation | 2 | 2016 | 38 | 0.070 |
Why?
|
| Mice | 1 | 2014 | 4396 | 0.060 |
Why?
|
| Male | 3 | 2016 | 12842 | 0.060 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 14 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 26 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 15 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 42 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 74 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 177 | 0.050 |
Why?
|
| Animals | 1 | 2014 | 9932 | 0.050 |
Why?
|
| Disease Management | 1 | 2021 | 84 | 0.040 |
Why?
|
| Lymphocyte Transfusion | 1 | 2020 | 1 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2020 | 83 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 165 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 315 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 142 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 9 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 34 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 37 | 0.040 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2016 | 1 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2016 | 36 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 233 | 0.030 |
Why?
|
| Cadaver | 1 | 2016 | 57 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 316 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 102 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 24 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2015 | 18 | 0.030 |
Why?
|
| Acute Disease | 1 | 2015 | 156 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2015 | 52 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2015 | 114 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 509 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 78 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 400 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 748 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2015 | 605 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 2261 | 0.020 |
Why?
|